Company Overview
TherapeuticsMD, Inc. operates as a specialized pharmaceutical royalty company based in the United States, focusing on the commercialization of specific prescription products through strategic license agreements. The firm holds a licensing arrangement with Mayne Pharma to bring to market the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products, which are distributed under the BocaGreenMD and vitaMedMD brand names. This entity functions within the broader Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, positioning it as a niche player rather than a broad-based pharmaceutical giant. As of the latest data, the company holds a market capitalization of $24.31M and reports trailing twelve-month revenue of $2.80M, supported by a workforce consisting of 1 employee. These valuation and revenue figures indicate that the company operates on a micro-cap scale with extremely limited human resources, suggesting a lean operational model where financial performance is heavily dependent on the success of its licensed product portfolio rather than traditional manufacturing or extensive internal research and development capabilities.
Financial Health
TherapeuticsMD reported trailing twelve-month revenue of $2.80M and a net income of $73,000, while its EBITDA stands at -$1,323,000. The significant disparity between the positive net income of $73,000 and the negative EBITDA of -$1,323,000 reveals a distinct cost structure where non-operating expenses, such as interest payments or one-time charges, are substantial enough to turn operating earnings negative despite the generation of profit on the income statement. The company generated free cash flow of -$1,394,750, which indicates a lack of current financial flexibility and a reliance on existing cash reserves to fund operations and potential growth initiatives. The company maintains a cash balance of $7.12M against total debt of $6.48M, resulting in a debt-to-equity ratio of 23.62, which suggests a balance sheet that is moderately leveraged but currently supported by a cash buffer exceeding its debt obligations. Liquidity is further supported by a current ratio of 2.93, indicating that the company possesses nearly three times the current assets required to cover its short-term liabilities without immediate distress. Regarding return metrics, the Return on Equity is 0.3% and the Return on Assets is -2.7%, which reveals that management effectiveness is currently constrained by the negative operating environment generated by high interest or administrative costs relative to the small asset base.
Valuation Assessment
The stock carries a trailing P/E ratio of 210.00 and a forward P/E of 6.00, a massive divergence that implies the market expects a dramatic turnaround in earnings or significant cost reductions that would allow the forward multiple to materialize, though such a trajectory is not guaranteed based on current operating conditions. The price-to-book ratio is 0.89, indicating that the market values the company at a discount to its book value, which often occurs in distressed situations or when intangible assets are undervalued on the balance sheet. Alternative valuation metrics further illustrate this dichotomy, with a price-to-sales ratio of 8.69 and an EV/EBITDA of -17.89, suggesting that traditional earnings-based valuation is impossible due to negative EBITDA, forcing reliance on sales multiples that are high for a micro-cap firm. The stock has traded between a 52-week high of $2.95 and a 52-week low of $0.83, meaning the current price sits significantly below the annual peak, reflecting the negative EBITDA and the pressure of high operating expenses relative to its tiny revenue stream. The beta value is 0.54, which signifies that the stock exhibits lower price volatility relative to the broader market, moving less aggressively than the S&P 500 despite its speculative nature as a micro-cap biopharma royalty firm.
Growth & Income
Revenue growth for the trailing twelve months is 43.3%, while earnings growth is listed as N/A due to the immaterial net income of $73,000, making a year-over-year comparison statistically insignificant. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders but instead retains earnings to fund operations or potential strategic acquisitions. The high revenue growth rate of 43.3% suggests that the company is successfully expanding its sales of licensed products like IMVEXXY and BIJUVA, yet the lack of earnings growth data highlights that this top-line expansion has not yet translated into scalable profitability given the fixed costs and interest burdens. Overall, the growth and income profile is characterized by rapid top-line expansion supported by a cash-rich balance sheet, but the absence of dividends and negative EBITDA indicates that the primary driver of shareholder value is capital appreciation rather than income generation or consistent operational profit.